Author Archives: NeuroPerspective

Mr. Robot and the Amyloid Hypothesis

“Maybe we’re all just stumbling from the right questions to the wrong answers, or maybe from the right answers to the wrong questions.”                                   … Continue reading

Posted in Uncategorized | 1 Comment

Sola’s EXPEDITION3 Fails

Back in 2013, NIR used a picture of an ill-fated South Pole expedition in a presentation at CNS Summit. The caption read: “Lilly announced it will run another major Phase III program for solanezumab. Patients must show scan or CSF … Continue reading

Posted in Uncategorized | Leave a comment

Alkermes, ALKS5461, and the FDA

Alkermes late yesterday announced that the third of the ALKS 5461 antidepressant Phase III trials had yielded positive results for the high dose, utilizing an SPCD trial design and an alternative parsing of the MADRS as the primary endpoint. The … Continue reading

Posted in Biotech, Muddled Media | Tagged , , , , , , | Leave a comment

Cosmetic Changes at GSK

Those–including NIR–who have been watching the GSK plan-for-succession as an indicator of GSK’s motivation to reassume a leadership role in pharmaceuticals, which by definition would include neuroscience, were disappointed by the GSK Board’s decision to anoint GSK’s consumer division head, … Continue reading

Posted in Big Pharma | Tagged , , , | Leave a comment

Praying and Paying for Hope

The FDA’s approval of Sarepta Therapeutics’ eteplirsen for Duchenne Muscular Dystrophy (DMD) turned the spotlight on a decision process that has tapped fundamental fissures within the FDA and the scientific community, fractures that could reverberate in far larger scale in … Continue reading

Posted in Big Pharma, Biotech | Tagged , , | Leave a comment

Allergan Gets It Right

It had seemed for a while that the headlines only reinforced the common public perception that the pharma industry had devolved into a snake pit of self-centered greed. Led by the Three Horsemen of the Pharmapocalypse, Shkreli, Pearson, and Bresch … Continue reading

Posted in Big Pharma, Biotech | Tagged , , , , , , | Leave a comment

Academic Opioid Leapfrogs Field–Perhaps

Nature was the venue (8/18/16) for the publication of a paper from academic collaborators at UCSF, Stanford, UNC, Friedrich-Alexander-Universität Erlangen-Nürnberg, and Parelcus Medical University, a paper that reported the development of a highly refined, selective mu opioid agonist that–in animal … Continue reading

Posted in Biotech, Science | Tagged , , | Leave a comment